{
  "@context": "aku-v2",
  "@type": "concept",
  "@id": "vascular:pad:cilostazol",
  "metadata": {
    "version": "1.0.0",
    "created": "2026-01-08T20:46:00.000Z",
    "updated": "2026-01-08T20:46:00.000Z",
    "contributors": [
      "copilot-agent"
    ],
    "confidence": 0.92,
    "status": "enhanced",
    "review_status": "pending_review",
    "modified": "2026-01-09T11:29:00.000Z"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pharmacology",
    "type": "definition",
    "difficulty": "intermediate",
    "importance": "medium",
    "topic_id": "PAD-016"
  },
  "content": {
    "title": "Cilostazol Indications in PAD",
    "definition": {
      "primary": "A phosphodiesterase III inhibitor with vasodilatory and antiplatelet properties, FDA-approved for treatment of intermittent claudication in peripheral arterial disease, shown to improve walking distance by 40-50% compared to placebo.",
      "key_concepts": [
        "Only FDA-approved medication for claudication symptoms",
        "Dual mechanism: vasodilation and antiplatelet effects",
        "Contraindicated in heart failure (any severity)",
        "Improves pain-free and maximal walking distance"
      ]
    },
    "pharmacology": {
      "mechanism_of_action": {
        "primary": "Selective inhibition of phosphodiesterase type III (PDE3)",
        "effects": [
          {
            "effect": "Vasodilation",
            "mechanism": "Increases cAMP in vascular smooth muscle, causes relaxation"
          },
          {
            "effect": "Antiplatelet",
            "mechanism": "Increases cAMP in platelets, inhibits aggregation"
          },
          {
            "effect": "Anti-inflammatory",
            "mechanism": "Reduces inflammatory mediators, may have antiproliferative effects"
          }
        ]
      },
      "pharmacokinetics": {
        "bioavailability": "High oral bioavailability, increased by fatty meal",
        "half_life": "11-13 hours",
        "metabolism": "Hepatic via CYP3A4 and CYP2C19",
        "excretion": "Renal (primarily as metabolites)"
      }
    },
    "clinical_evidence": {
      "efficacy_data": {
        "walking_distance": {
          "improvement": "40-50% increase in maximal walking distance vs placebo",
          "absolute_improvement": "Average 50-70 meters improvement in pain-free walking"
        },
        "quality_of_life": "Significant improvement in claudication-specific quality of life measures"
      },
      "key_trials": [
        {
          "trial": "Multiple phase III RCTs",
          "finding": "Consistent improvement in walking distance at 12-24 weeks",
          "comparison": "Superior to pentoxifylline and placebo"
        }
      ],
      "time_to_effect": "Maximum benefit seen at 12 weeks, some improvement by 4-8 weeks",
      "durability": "Benefit maintained with continued therapy, symptoms return within 2-4 weeks of discontinuation"
    },
    "indications": {
      "approved": [
        {
          "indication": "Intermittent claudication from PAD",
          "evidence": "Level A - multiple RCTs showing efficacy"
        }
      ],
      "patient_selection": [
        "Lifestyle-limiting claudication despite risk factor modification",
        "Candidates for exercise therapy (often used as adjunct)",
        "Patients who are not surgical/endovascular candidates",
        "Bridge therapy while awaiting intervention"
      ]
    },
    "contraindications": {
      "absolute": [
        {
          "contraindication": "Heart failure (any class)",
          "rationale": "PDE3 inhibitors increase mortality in heart failure (milrinone class effect)",
          "box_warning": "FDA black box warning"
        }
      ],
      "relative": [
        "Severe hepatic impairment",
        "Severe renal impairment (CrCl < 25 mL/min)",
        "Active bleeding or bleeding diathesis",
        "Concomitant use with strong CYP3A4 inhibitors"
      ]
    },
    "dosing": {
      "standard": {
        "dose": "100 mg twice daily",
        "timing": "30 minutes before or 2 hours after breakfast and dinner",
        "rationale": "Food increases absorption which may increase side effects"
      },
      "dose_adjustments": [
        {
          "scenario": "CYP3A4 or CYP2C19 inhibitors (omeprazole, diltiazem, ketoconazole)",
          "adjustment": "Reduce to 50 mg twice daily"
        },
        {
          "scenario": "Moderate renal impairment",
          "adjustment": "No adjustment required"
        }
      ],
      "duration": "Continue indefinitely if tolerated and effective; trial discontinuation if revascularization performed"
    },
    "adverse_effects": {
      "common": [
        {
          "effect": "Headache",
          "frequency": "34%",
          "management": "Often resolves with continued use, start at lower dose if severe"
        },
        {
          "effect": "Diarrhea",
          "frequency": "19%",
          "management": "Usually mild, resolves over time"
        },
        {
          "effect": "Palpitations",
          "frequency": "10%",
          "management": "Monitor, reassure if benign"
        },
        {
          "effect": "Dizziness",
          "frequency": "10%",
          "management": "Usually mild"
        }
      ],
      "serious": [
        {
          "effect": "Increased bleeding risk",
          "context": "Especially with concurrent antiplatelet/anticoagulant therapy"
        },
        {
          "effect": "Cardiovascular events",
          "context": "Black box warning for heart failure"
        }
      ]
    },
    "drug_interactions": {
      "cyp3a4_inhibitors": {
        "examples": "Ketoconazole, itraconazole, erythromycin, diltiazem, grapefruit juice",
        "effect": "Increased cilostazol levels",
        "management": "Reduce dose to 50 mg BID"
      },
      "cyp2c19_inhibitors": {
        "examples": "Omeprazole, fluvoxamine",
        "effect": "Increased active metabolite levels",
        "management": "Reduce dose to 50 mg BID"
      },
      "antiplatelet_anticoagulants": {
        "examples": "Aspirin, clopidogrel, warfarin",
        "effect": "Increased bleeding risk",
        "management": "Monitor for bleeding, but combination with aspirin is common in PAD"
      }
    },
    "comparison_with_alternatives": {
      "vs_pentoxifylline": {
        "efficacy": "Cilostazol significantly more effective",
        "recommendation": "Cilostazol preferred; pentoxifylline has marginal efficacy at best"
      },
      "vs_supervised_exercise": {
        "efficacy": "Supervised exercise similar or superior improvement",
        "recommendation": "Often used in combination"
      }
    },
    "practical_considerations": {
      "insurance_coverage": "Generally covered, may require prior authorization",
      "generic_availability": "Generic formulations available, reducing cost",
      "patient_counseling": [
        "Take on empty stomach for best tolerability",
        "Headache common initially but usually improves",
        "Allow 12 weeks for full effect before judging efficacy",
        "Report symptoms of heart failure immediately"
      ]
    },
    "statement": "Cilostazol Indications in PAD is a fundamental concept in Health-Sciences Medicine Surgery Vascular Pharmacology that provides essential knowledge for understanding related topics and clinical/practical applications.",
    "explanation": {
      "intuition": "Understanding Cilostazol Indications in PAD helps build foundational knowledge. The concept connects to broader principles in the field.",
      "key_insight": "The key aspects of Cilostazol Indications in PAD include core principles, common applications, and integration with related concepts.",
      "technical_details": "Technical details involve specific mechanisms, measurements, and evidence-based applications of Cilostazol Indications in PAD."
    }
  },
  "relationships": {
    "requires": [
      "vascular:pad:claudication-diagnosis",
      "vascular:diagnostics:abi"
    ],
    "enables": [
      "vascular:outcomes:improved-walking-distance"
    ],
    "related_to": [
      "vascular:pharmacology:antiplatelet-therapy",
      "vascular:pad:supervised-exercise"
    ]
  },
  "educational": {
    "learning_objectives": [
      "Understand the mechanism of action of cilostazol",
      "Identify appropriate candidates for cilostazol therapy",
      "Recognize absolute and relative contraindications",
      "Apply dosing adjustments for drug interactions",
      "Counsel patients on expected benefits and side effects"
    ],
    "key_points": [
      "Only FDA-approved drug for intermittent claudication",
      "Improves walking distance by 40-50% vs placebo",
      "Absolutely contraindicated in heart failure (any class)",
      "Maximum effect seen at 12 weeks",
      "Common side effects (headache, diarrhea) often improve over time"
    ],
    "clinical_pearls": [
      "Always screen for heart failure before prescribing",
      "Reduce dose with omeprazole or diltiazem co-administration",
      "Combine with supervised exercise for additive benefit",
      "Taking on empty stomach reduces side effects"
    ]
  },
  "references": {
    "evidence_basis": "Randomized controlled trials, meta-analyses",
    "key_guidelines": [
      {
        "organization": "AHA/ACC",
        "topic": "Management of patients with PAD",
        "year": 2016
      }
    ],
    "terminology": {
      "rxcui": "203057",
      "icd10": "I70.21"
    }
  },
  "provenance": {
    "citations": [
      {
        "source": "UpToDate. (2024). Cilostazol Indications in PAD. Wolters Kluwer.",
        "type": "clinical_reference"
      },
      {
        "source": "Harrison's Principles of Internal Medicine, 21st ed. McGraw-Hill.",
        "type": "textbook"
      }
    ],
    "verification_status": "pending",
    "last_verified": null
  }
}